isvav_result

publication_year

occurrences__organization__code

solver__id__sc2

result_type__code

Type of result according to the RIV classification. Czech version is available <a href="https://www.vyzkum.cz/FrontClanek.aspx?idsekce=1395" target="_blank" >here</a>.

language__code

Jazyk výsledku udáva původní jazyk, ve kterém byl daný výsledek vytvořen. Kompletní seznam jazyků ve kterém je možno výsledek do RIV předložit je <a href="https://www.vyzkum.cz/FrontClanek.aspx?idsekce=1397" target="_blank" >zde</a>.

cep__code

ford__code

_group_id67

occurrences__funder__code

Data supplier is the R&D aid provider who supported this result.

project__programme__code

x_range_count_solvers

project__id

What are you looking for?

Quick search

Smart search

Filters

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse.

Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma